MedTrace Logo

Hepatitis C Treatment of Inmates

NCT00209898 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2015-03-20

No results posted yet for this study

Summary

Hepatitis C infection is a prevalent chronic disease. It is particularly prevalent among intravenous drug abusers. Bergen fengsel is a regional prison housing 250 inmates, of which as many as 70 are recorded HCV RNA PCR positive annuallly. In this study inmate males and females will be randomized to standard screening and initiation procedure, or to a rapid initiation procedure in the hospital's infectious diseases outpatient clinic. The study aims at studying if rapid inclusion will increase the possibility to conclude treatment while the prisoner still is incarcerated, thus improve the chances of reaching a sustained virologic response, compared to standard inclusion, where prisoners, as other out patients will wait for inclusion for several months.

Conditions

  • Chronic Hepatitis C

Interventions

PROCEDURE

Fast initiation procedure

Sponsors & Collaborators

  • Bergen Prison, Norwegian Correctional Service

    collaborator OTHER

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Steinar Skrede, M.D., Ph.D. · Unit for infectious diseases, Dept. Internal Medicine, Haukeland UH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209898 on ClinicalTrials.gov